Mission NMD Pharma is dedicated to developing novel treatments to improve muscle function and quality of life of patients with neuromuscular disease. Vision A future in which patients with neuromuscular disease live better and more independent lives. We have a unique translational muscle electrophysiology platform leveraging in-depth know-how of muscle physiology and muscular disorders for discovering and developing first-in-class therapeutics in neuromuscular diseases with a significant unmet medical need. NMD Pharma is the leading company utilizing ClC-1 Cl- ion channel inhibitors for neuromuscular diseases and currently has one clinical-stage product candidate for the treatment of myasthenia gravis. We have more than 25 employees with expertise in all areas of drug development. We are headquartered in Aarhus, Denmark, and collaborate with internationally renowned companies and key opinion leaders in the field of neuromuscular diseases. For more information, please visit the company website.
| Website | http://www.nmdpharma.com |
| Revenue | $8.4 million |
| Employees | 78 (51 on RocketReach) |
| Founded | 2015 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+4 more
(view full list)
|
| Industry | Biotechnology, Drug Discovery |
| Keywords | Rare Disease Treatment, Muscular Dystrophy Treatment, Patient Quality Of Life, Neuromuscular Disorders, Muscle Health, Independent Living, Novel Therapies, Regenerative Medicine, Drug Development, Advanced Therapies, Pharmaceutical Research, Genetic Diseases, Clinical Trials, Pharmaceutical, Biotechnology |
| Competitors | Amgen, Biogen, Acorda Therapeutics, Inc., Sage Therapeutics, Karyopharm Therapeutics Inc., Neuren Pharmaceuticals, Axovant Sciences Ltd, Viela Bio, Lilly India, Greenwich LifeSciences, Inc. +39 more (view full list) |
Looking for a particular NMD Pharma A/S employee's phone or email?
The NMD Pharma A/S annual revenue was $8.4 million in 2026.
Thomas Pedersen is the CEO of NMD Pharma A/S.
51 people are employed at NMD Pharma A/S.